Eli Lil­ly touts sky­rock­et­ing Moun­jaro pre­scrip­tions even as it re­ports an over­all slump in 2022 rev­enue

Eli Lil­ly is bet­ting big on its type 2 di­a­betes drug Moun­jaro amid sky­rock­et­ing pre­scrip­tions since its launch.

The com­pa­ny ex­pects US net prices to con­tin­ue to in­crease as ac­cess is broad­ened and paid pre­scrip­tions for the drug al­so in­crease.

Pre­scrip­tions for Moun­jaro peaked at about 180,000 per week in De­cem­ber, far out­pac­ing its own es­tab­lished type 2 drug Trulic­i­ty, ac­cord­ing to Lil­ly da­ta re­port­ed in its earn­ings re­port on Thurs­day. While Moun­jaro on­ly brought in Q4 rev­enue of $279.2 mil­lion, it’s ex­pect­ed to quick­ly be­come a block­buster.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER